InflaRx (IFRX) Debt to Equity (2020 - 2022)

InflaRx's (IFRX) quarterly Debt to Equity came in at $0.0 in Q3 2022, up 12.89% quarter-over-quarter from $0.0 in Q2 2022.

InflaRx (IFRX) Debt to Equity (2020 - 2022) Analysis & Trends

InflaRx has disclosed Debt to Equity across 3 years of filings, most recently posting $0.0 for Q3 2022.

  • Debt to Equity for Q3 2022 came in at $0.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $0.0 (changed N/A YoY), and the FY2021 annual result was $0.0, down 13.18% from the prior year.
  • Debt to Equity came in at $0.0 for Q3 2022 at InflaRx, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.0 in Q1 2021 to a low of $0.0 in Q2 2021.
  • The 3-year median for Debt to Equity is $0.0 (2022), against an average of $0.0.
  • Peak annual rise in Debt to Equity reached 26.22% in 2022, while the deepest fall reached 46.47% in 2022.
  • InflaRx's Debt to Equity stood at $0.0 in 2020, then decreased by 13.18% to $0.0 in 2021, then increased by 9.75% to $0.0 in 2022.
  • The last three Debt to Equity figures came in at $0.0 (Q3 2022), $0.0 (Q2 2022), and $0.0 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 InflaRx 764.68 Mn 764.68 Mn 10,877.40 -

Historic Data

Download Data
DateValue
Sep 30, 2022 0.00
Jun 30, 2022 0.00
Mar 31, 2022 0.00
Dec 31, 2021 0.00
Jun 30, 2021 0.00
Mar 31, 2021 0.00
Dec 31, 2020 0.00